Martínez-Luna E, Rebollo DN, Calvillo MP

Language: Spanish
References: 11
Page: 213-214
PDF size: 74.84 Kb.

Text Extraction

No abstract.

REFERENCES

1. Vitiello GA, Lee AY y Berman RS, Dermatofibrosarcoma protuberans:what is this?, Surg Clin North Am 2022; 102(4):657-65.

2. Allen A, Ahn C y Sangüeza OP, Dermatofibrosarcoma protuberans,Dermatol Clin 2019; 37(4):483-8.QUIZ

3. Mujtaba B, Wang F, Taher A, Aslam R, Madewell JE, Spear R yNassar S, Dermatofibrosarcoma protuberans: pathological andimaging review, Curr Probl Diagn Radiol 2021; 50(2):236-40.

4. Lim SX, Ramaiya A, Levell NJ y Venables ZC, Review of dermatofibrosarcomaprotuberans, Clinical and Experimental Dermatology2023; 48(4):297-302.

5. Llombart B, Serra C, Requena C, Alsina M, Morgado-CarrascoD, Través V et al., Sarcomas cutáneos: directrices para el diagnósticoy tratamiento, Dermatofibrosarcoma protuberans, ActasDermosifiliogr 2018; 868-77.

6. Xiong D y Bordeaux J, Incidence and survival outcomes of dermatofibrosarcomaprotuberans from 2000 to 2020: a population-based retrospective cohort analysis, Dermatologic Surgery2023; 49:1096-103.

7. Badhey A, Tikhtman R y Tang A, Management of dermatofibrosarcomaprotuberans, Current Opinion in Otolaryngology &Head & Neck Surgery 2021; 29:278-82.

8. Hao X, Billings SD, Wu F, Stultz TW, Procop GW, Mirkin G y VidimosAT, Dermatofibrosarcoma protuberans: update on the diagnosisand treatment, J Clin Med 2020; 9(6):1752.

9. Brooks J y Ramsey ML, Dermatofibrosarcoma protuberans,StatPearls, Treasure Island (FL), StatPearls Publishing, 2024.pmid: 30020677.

10. Houdek MT, Tsoi KM, Mallett KE, Claxton RM, Ferguson PC,Griffin AM, Baum CL, Brewer JD, Rose PS y Wunder JS, Surgicaloutcomes of primary dermatofibrosarcoma protuberans:a retrospective, multicenter study, Ann Surg Oncol 2022;29(13):8632-8.

11. Gómez‐Pedraza A y Ledesma-Martín F, Dermatofibrosarcomaprotuberans facial gigante. Reporte de un caso y revisión de laliteratura, Gaceta Mexicana de Oncología 2021; 20(91).